115 related articles for article (PubMed ID: 20005102)
1. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
[TBL] [Abstract][Full Text] [Related]
2. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Ko JH; Yeon SW; Ryu JS; Kim TY; Song EH; You HJ; Park RE; Ryu CK
Bioorg Med Chem Lett; 2006 Dec; 16(23):6001-5. PubMed ID: 16990001
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
[TBL] [Abstract][Full Text] [Related]
5. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
[TBL] [Abstract][Full Text] [Related]
6. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
7. Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Kettle JG; Brown S; Crafter C; Davies BR; Dudley P; Fairley G; Faulder P; Fillery S; Greenwood H; Hawkins J; James M; Johnson K; Lane CD; Pass M; Pink JH; Plant H; Cosulich SC
J Med Chem; 2012 Feb; 55(3):1261-73. PubMed ID: 22248236
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
Fuchi N; Iura Y; Kaneko H; Nitta A; Suyama K; Ueda H; Yamaguchi S; Nishimura K; Fujii S; Sekiya Y; Yamada M; Takahashi T
Bioorg Med Chem Lett; 2012 Jul; 22(13):4358-61. PubMed ID: 22633690
[TBL] [Abstract][Full Text] [Related]
9. New thiazole carboxamides as potent inhibitors of Akt kinases.
Chang S; Zhang Z; Zhuang X; Luo J; Cao X; Li H; Tu Z; Lu X; Ren X; Ding K
Bioorg Med Chem Lett; 2012 Jan; 22(2):1208-12. PubMed ID: 22172705
[TBL] [Abstract][Full Text] [Related]
10. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.
Seefeld MA; Rouse MB; McNulty KC; Sun L; Wang J; Yamashita DS; Luengo JI; Zhang S; Minthorn EA; Concha NO; Heerding DA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2244-8. PubMed ID: 19285393
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
Hu H; Wang X; Chan GK; Chang JH; Do S; Drummond J; Ebens A; Lee W; Ly J; Lyssikatos JP; Murray J; Moffat JG; Chao Q; Tsui V; Wallweber H; Kolesnikov A
Bioorg Med Chem Lett; 2015 Nov; 25(22):5258-64. PubMed ID: 26459208
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of indazole based analog sensitive Akt inhibitors.
Okuzumi T; Ducker GS; Zhang C; Aizenstein B; Hoffman R; Shokat KM
Mol Biosyst; 2010 Aug; 6(8):1389-402. PubMed ID: 20582381
[TBL] [Abstract][Full Text] [Related]
15. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
16. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
[TBL] [Abstract][Full Text] [Related]
18. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
Zhu GD; Gandhi VB; Gong J; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Jarvis K; Park C; Jong RD; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jul; 16(13):3424-9. PubMed ID: 16644221
[TBL] [Abstract][Full Text] [Related]
19. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Luo Y; Shoemaker AR; Liu X; Woods KW; Thomas SA; de Jong R; Han EK; Li T; Stoll VS; Powlas JA; Oleksijew A; Mitten MJ; Shi Y; Guan R; McGonigal TP; Klinghofer V; Johnson EF; Leverson JD; Bouska JJ; Mamo M; Smith RA; Gramling-Evans EE; Zinker BA; Mika AK; Nguyen PT; Oltersdorf T; Rosenberg SH; Li Q; Giranda VL
Mol Cancer Ther; 2005 Jun; 4(6):977-86. PubMed ID: 15956255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
